Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025

Accuray to Host Analyst Event at the American Society of Radiation Oncology Meeting on September 29, 2025

Event Will Feature Global KOLs Sharing Their Perspectives on the Role of Adaptive Radiotherapy in Radiation Medicine

Accuray Incorporated (NASDAQ: ARAY) announced today that the company will host a discussion with analysts and investors on Monday, September 29, 2025 in conjunction with the American Society of Radiation Oncology (ASTRO) Annual Meeting in San Francisco, California . The event will take place in person at the ASTRO meeting and on a virtual platform, with presentations beginning at 1:30 pm PT ( 4:30 pm ET ).

Analysts participating in the event will have a unique opportunity to hear first-hand from global thought leaders who will share their perspectives on the role of adaptive radiotherapy in radiation medicine. Topics include:

  • The Adaptive Radiotherapy Spectrum & Programmatic Vision
  • Integration of Adaptive Radiotherapy into Practice & Workflow Realities
  • Motion Management & Imaging Leadership: The Global Perspective

Both in-person and virtual guests must register in advance to participate in the Accuray meeting. Please RSVP here by September 25, 2025 .

About Accuray
Accuray Incorporated (Nasdaq: ARAY) is committed to expanding the powerful potential of radiation therapy to improve as many lives as possible. We invent unique, market-changing solutions that are designed to deliver radiation treatments for even the most complex cases – while making commonly treatable cases even easier – to meet the full spectrum of patient needs. We are dedicated to continuous innovation in radiation therapy for oncology, neuro-radiosurgery, and beyond, as we partner with clinicians and administrators, empowering them to help patients get back to their lives, faster. Accuray is headquartered in Madison, Wisconsin , with facilities worldwide.

Investor Contact
Aman Patel , CFA
Investor Relations, ICR Healthcare
+1 (443) 450-4191
aman.patel@westwicke.com

Media Contact
Beth Kaplan
Public Relations Director, Accuray
bkaplan@accuray.com

Cision View original content to download multimedia: https://www.prnewswire.com/news-releases/accuray-to-host-analyst-event-at-the-american-society-of-radiation-oncology-meeting-on-september-29-2025-302554133.html

SOURCE Accuray Incorporated

News Provided by PR Newswire via QuoteMedia

ARAY
The Conversation (0)
Nextech3D.ai Announces New 3D Model Deals Continuing to Drive Its Growth, As Company Surpasses 37,700 3D Models Produced

Nextech3D.ai Announces New 3D Model Deals Continuing to Drive Its Growth, As Company Surpasses 37,700 3D Models Produced

The Company would also like to announce the appointment of Nidhi Kumra, CA, CPA, to the Board of Directors and as the Audit Committee Chair Replacing Jeff DawleyNextech3D.ai (formally "Nextech AR Solutions Corp'' or the "Company") (OTCQX:NEXCF)(CSE:NTAR)(FSE:EP2), a Generative AI-Powered 3D... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 3 Small-cap Medical Device Stocks (Updated January 2026)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Medical devices on a desk.

How to Invest in Medical Device Stocks and ETFs

The medical device market offers investors unique exposure to the overall life science space, especially in an era of fast-growing tech advancements in healthcare.This industry covers a wide range of health and medical instruments and equipment used in the treatment, mitigation, diagnosis and... Keep Reading...
illustration of brain and cell phone.

BlinkLab Completes First Patient Test for US Autism Diagnostic Study

Digital healthcare company BlinkLab (ASX:BB1) has tested the first patient in its US autism diagnostic study, which is geared at validating the company's Dx1 test as a diagnostic aid for clinicians. BlinkLab states in its Wednesday (March 12) release that the study is the largest digital... Keep Reading...
Female doctor with clipboard talking to smiling female patient at hospital.

Revolutionizing Women's Health: Antifungal Innovation Brings New Investment Opportunities

The intersection of women's health and antifungal innovation represents a pivotal moment in healthcare, offering both transformative medical advancements and compelling investment opportunities. The groundbreaking developments in antifungal treatments specifically targeting women's health issues... Keep Reading...
Stethoscope connected to a phone with medical data overlay.

Top 5 Small-cap Medical Device Stocks (Updated January 2025)

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).Wearable medical devices and the use of artificial intelligence in medical... Keep Reading...
Zero Candida Technologies (TSXV:ZCT)

Zero Candida Announces Plans to Complete Preclinical Studies for FDA Submission by Q3 2025

Zero Candida Technologies, Inc. (TSXV: ZCT), (FSE: 9L2) (the "Company" or "ZCT"), an Israeli FemTech medical device company focused on revolutionizing women's health, announces plans to complete preclinical studies for FDA submission by Q3 2025. In accordance with FDA requirements, the company... Keep Reading...

Interactive Chart

Latest Press Releases

Related News